Navigation Links
Micromet Announces Pricing of Public Offering of Common Stock
Date:7/30/2009

all, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Inc. ("OriGene") today announced it has raised an ... With this financing, OriGene completed the acquisition of ... a manufacturer and provider of monoclonal antibodies (mAb) ... completes the establishment of its technology center to ...
... NKTR ) will announce its financial results ... on Wednesday, February 25, 2009, after the close,of U.S.-based ... will host a conference call to review the results ... (PT). , The press release ...
... VALLEY COTTAGE, N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... Mr.,David Grossman and Mr. Boaz Shweiger have been appointed ... Mr. Grossman will also be assuming,the role of Co-Chief ... of its strategic alternatives. , ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... Researchers at Albany Medical College are releasing results of a ... search for new drug targets aimed at preventing or reversing ... stroke. In the March 5 issue of the ... and his colleagues at the college,s Center for Cardiovascular Science ...
... , This release is available in German . ... beewolves, house beneficial bacteria on their cocoons that guarantee ... Institute for Chemical Ecology in Jena teamed up with ... Leibniz Institute for Natural Product Research Hans-Knoell-Institute - ...
... African-Americans age 65 and younger are more than twice ... any region, and people who have a stroke are more ... researchers at the University of Alabama at Birmingham (UAB) School ... for Geographic and Racial Differences in Stroke (REGARDS) study, one ...
Cached Biology News:Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach 2Beewolves protect their offspring with antibiotics 2Beewolves protect their offspring with antibiotics 3UAB study shows African-Americans have highest stroke rate, southerners more likely to die 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: